Duloxetine in the Prevention of Depressive Recurrences: A Randomized, Double-Blind, Placebo-Controlled Trial
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
Objective To assess the efficacy of duloxetine 60-120 mg once daily in the prevention of depressive recurrence in outpatients with recurrent major depressive disorder (MDD). Method Eligible patients with at least 3 episodes of MDD (DSM-IV diagnosis) in the past 5 years received open-label duloxetine 60-120 mg/day for up to 34 weeks. Patients meeting response criteria were then randomly assigned to either duloxetine or placebo for up to 52 weeks of double-blind maintenance treatment. The primary outcome measure was time to recurrence of a major depressive episode. Safety and tolerability were assessed via analysis of treatment-emergent adverse events (TEAEs), vital signs, weight, and laboratory measures. Patients were recruited from 43 study centers in 5 European countries (France, Germany, Italy, Russia, and Sweden) and the United States. The study was conducted from March 2005 to January 2008. Results A total of 288 patients were randomly assigned to duloxetine or placebo. Time to a depressive recurrence was significantly longer in duloxetine-treated patients compared with placebo-treated patients (p Conclusions Treatment with duloxetine was associated with a longer time to depressive recurrence and a significantly lower recurrence rate compared with placebo. Trials registration (ClinicalTrials.gov) Identifier: NCT00105989.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Perahia 2009 reported a difference in the SF-36 mental component summary mean change score, favouring continuation of antidepressant: -5.74 (SE 1.2) in the discontinuation group (n = 142) and -1.11 (SE 1.11) in the continuation group (n = 146) (P = 0.002)”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Perahia 2009
In the citing paper
“and no difference in the SF-36 physical component summary score: 0.33 (SE 0.76) in the discontinuation group and -0.45 (SE 0.7) in the continuation group (P = 0.415).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Perahia 2009
In the citing paper
“Participants in the discontinuation group (n = 142) reported a higher score for Sheehan Disability Scale global functioning compared to those in the antidepressant group (n = 145) (mean change (SE) 2.06 (0.77) in the discontinuation group and -0.05 (0.71) in the antidepressant group; P = 0.029; increase in score signifies worsening).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Perahia 2009
In the citing paper
“Perahia 2009 (n = 288) reported no suicide attempts.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Perahia 2009
Citations
Cites
Still being checked.
Cited by
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
“Some patients fi nd that a single daily dose facilitates long-term treatment adherence and A, RG 2) and duloxetine (Perahia et al. 2009; Kelin et al. 2010) (CE A, RG 2) and vortioxetine (Boulenger et al. 2012) (CE B, RG 3) are effective in preventing recurrence of depression.”
BackgroundKato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01824-z · Cited by 136
Pergolizzi, J. V., Raffa, R. B., Taylor, R., Rodriguez, G., Nalamachu, S. R., & Langley, P. C. (2012) · Pain Practice · doi:10.1111/j.1533-2500.2012.00578.x · Cited by 121
Andrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., & Neale, M. C. (2011) · Frontiers in Psychology · doi:10.3389/fpsyg.2011.00159 · Cited by 107
A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine
Rodrígues-Amorím, D., Olivares, J. M., Spuch, C., & Baltanás, T. R. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.554899 · Cited by 122
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Gueorguieva, R., Chekroud, A. M., & Krystal, J. H. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30038-x · Cited by 67
Psychosocial features of depression: A systematic literature review
Cabello, M., Mellor-Marsá, B., Sabariego, C., Cieza, A., Bickenbach, J. E., & Ayuso‐Mateos, J. L. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.12.009 · Cited by 73
Jindal, A., Mahesh, R., & Bhatt, S. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.08.005 · Cited by 54
Hammad, T. A., Pinheiro, S. P., & Neyarapally, G. A. (2011) · Clinical Trials · doi:10.1177/1740774511419165 · Cited by 46
Duloxetine and cardiovascular adverse events: A systematic review and meta-analysis
Park, K., Kim, S., Ko, Y.-J., & Park, B. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.02.022 · Cited by 47
A Review of Antidepressant Therapy in Primary Care: Current Practices and Future Directions
Kennedy, S. H. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01420 · Cited by 41
Jindal, A., Mahesh, R., & Bhatt, S. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.02.017 · Cited by 38
Montejo, A. L., David, P., Spann, M. E., Wang, F., Walker, D. J., Yang, C. R., & Detke, M. J. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02113.x · Cited by 33
Self-citationMancini, M., Wade, A. G., Perugi, G., Lenox-Smith, A., & Schacht, A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.01.001 · Cited by 28
Torta, R., Leombruni, P., Borio, R., & Castelli, L. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1202 · Cited by 26
Mancini, M., Perna, G., Rossi, A., & Petralia, A. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003747441 · Cited by 27
(2014) · Europe PMC (PubMed Central) · Cited by 24
Individual residual symptoms and functional impairment in patients with depression
Romera, I., Pérez, V., Quail, D., Berggren, L., Lenox‐Smith, A., & Gilaberte, I. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.07.042 · Cited by 26
Ball, S. G., Desaiah, D., Zhang, Q., Thase, M., & David, P. (2013) · Drugs in Context · doi:10.7573/dic.212245 · Cited by 26
Self-citationCrucitti, A., Zhang, Q., Nilsson, M., Brecht, S., Yang, C. R., & Wernicke, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003769241 · Cited by 22
Durgam, S., Gommoll, C., Migliore, R., Chen, C., Chang, C.-T., Aguirre, M., & Thase, M. E. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000236 · Cited by 16
Self-citationTreuer, T., Liu, C.-Y., Salazar, G., Kongsakon, R., Jia, F., Habil, H., Lee, M., Lowry, A. J., & Dueñas, H. (2013) · Asia-Pacific Psychiatry · doi:10.1111/appy.12090 · Cited by 16
Zhou, D., Lv, Z., Shi, L., Zhou, X., Lin, Q., Chen, X., Wan, L.-Y., Li, Y., Ran, L., Huang, Y., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720001610 · Cited by 14
Kelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D., & Perahia, D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02374.x · Cited by 11
Self-citationHuang, Y., Liang, X., Qian, L.-Q., Cai, C., Guo, J., Gao, C., Guan, J., & Zhao, G.-P. (2014) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-014-1787-x · Cited by 11
McGoldrick, A., Byrne, H., & Cadogan, C. A. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01602-z · Cited by 10
Oakes, T. M. M., Dellva, M. A., Waterman, K., Greenbaum, M., Poppe, C. J., Goldberger, C., AHL, J. S. B., & David, P. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1037732 · Cited by 11
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K. J., Lux, L. J., Noord, M. V., Mager, U., Gaynes, B. N., Thieda, P., Strobelberger, M., et al. (2011) · Cited by 8
Zaccoletti, D., Mosconi, C., Gastaldon, C., Benedetti, L., Gottardi, C., Papola, D., Ponzi, O., Purgato, M., Naudet, F., Cristea, I. A., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00330-x · Cited by 13
Arıkan, M. K., İlhan, R., Pogarell, O. M., & Metin, B. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.024 · Cited by 6
Alev, L., Lenox‐Smith, A., Altın, M., & Dueñas, H. (2013) · Open Journal of Depression · doi:10.4236/ojd.2013.24011 · Cited by 6
Shi, N., Cao, Z., Durden, E., Schacht, A., Torres, A., & Happich, M. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.672941 · Cited by 5
Pangallo, B. A., Zhang, Q., Desaiah, D., David, P., Detke, M. J., & Kennedy, S. H. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.522157 · Cited by 5
Self-citationWilhelm, S., Boess, F., Hegerl, U., Mergl, R., Linden, M., Schacht, A., & Schneider, E. M. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.699521 · Cited by 4
Laux, G., & Klimke, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_414 · Cited by 2
Pharmacotherapy of Major Depressive Disorder: Focus on Duloxetine
Muneoka, K. T. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s1988 · Cited by 5
Holsboer‐Trachsler, E., & Holsboer, F. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_53 · Cited by 2
Duloxetine in the acute and continuation treatment of major depressive disorder
Bochsler, L., Olver, J. S., & Norman, T. R. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.133 · Cited by 1
Satoi, Y., Harada, E., Shirakawa, O., Marangell, L. B., & Escobar, R. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s86598 · Cited by 2
Duloxetine: pharmacologic characteristics and clinical use
Sobów, T. (2015) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2015.0029
Laux, G., & Klimke, A. (2022) · Springer eBooks · doi:10.1007/978-3-319-56015-1_414-1 · Cited by 1
Depression : can we predict who will relapse?
Buckman, J. E. J. (2014) · UCL Discovery (University College London) · Cited by 2
Santone, G., Bellantuono, C., & Psichiatrica, C. (2009)
Grygorcewicz, O., Czachorowska, M., Szweda, F., Poczwardowski, T., Kaczmarek, A., Kowalska, K. A., Latos, J. T., Chwalczuk, M., Koneczna, M., Krystyniak, K. A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4659
Metadata
- Authors
- Perahia, D. G. S., Maina, G., Thase, M. E., Spann, M. E., Wang, F., Walker, D. J., & Detke, M. J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-05-15
- Volume
- 70
- Issue
- 5
- Pages
- 706-716
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2119772787
- Semantic Scholar
- 548833f8bef5c57994e0e8f4f298d7cd024d5f36
- Cited by
- 47
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 4 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 3
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- duloxetine, major depressive disorder, depression recurrence, prevention, maintenance therapy, antidepressants, outpatients, time to recurrence, adverse events
- MeSH terms
- Duloxetine Hydrochloride, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Thiophenes, Prevalence, Selective Serotonin Reuptake Inhibitors, Sex Distribution, Diagnostic and Statistical Manual of Mental Disorders, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.